About UCSF Search UCSF UCSF Medical Center

Frank McCormick, PhD, FRS, DSc (Hon)

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
mccormick_frank

Professor Emeritus, UCSF Helen Diller Family Comprehensive Cancer Center
David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research

mccormic@cc.ucsf.edu

Phone: (415) 502-1710 (voice)
Box 0128, UCSF
San Francisco, CA 94143-0128

View on UCSF Profiles


Additional Websites


Education

University of Birmingham, England, B.Sc., 1972, Biochemistry
University of Cambridge, England, Ph.D., 1975, Biochemistry


Professional Experience

  • 1975-78
    Professor Seymour S. Cohen, State University of New York at Stony Brook (Post Doctoral Fellow)
  • 1978-81
    Dr. Alan Smith, Imperial Cancer Research Fund, London (Post Doctoral Fellow)
  • 1981-90
    Cetus Corporation (Director of Molecular Biology)
  • 1990-91
    Cetus Corporation (Vice President, Research)
  • 1991-92
    Chiron Corporation (Vice President, Research)
  • 1992-96
    Onyx Pharmaceuticals (Founder, Chief Scientific Officer)
  • 1996-present
    Fellow of the Royal Society
  • 1997-2009
    University of California, San Francisco, Cancer Research Institute (Director)
  • 1997-present
    University of California, San Francisco, Dept. of Microbiology & Immunology (Professor)
  • 1997-
    University of California, San Francisco, Cancer Center, (Director, Associate Dean)

Honors & Awards

  • 1996
    Fellow of the Royal Society
  • 2002
    Bristol Myers Squibb Unrestricted Cancer Research Grant
  • 2002
    AACR - G.H.A. Clowes Memorial Award
  • 2002
    Novartis Drew Award in Biomedical Research
  • 2003
    University of Chicago, Cancer Research Center, Shubitz Award
  • 2005
    Institute of Medicine
  • 2010
    ASCO Science of Oncology Award

Selected Publications

  1. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014 Jun 24; 14(7):455-67.
    View on PubMed
  2. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell. 2014 Mar 17; 25(3):272-81.
    View on PubMed
  3. Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, Tomasic G, Favre M, Vagner S, Robert C, Ghoddusi M, Daniel D, Pryer N, McCormick F, Stuart D. Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors. Cancer Res. 2014 Apr 15; 74(8):2238-45.
    View on PubMed
  4. Kashiyama T, Oda K, Ikeda Y, Shiose Y, Hirota Y, Inaba K, Makii C, Kurikawa R, Miyasaka A, Koso T, Fukuda T, Tanikawa M, Shoji K, Sone K, Arimoto T, Wada-Hiraike O, Kawana K, Nakagawa S, Matsuda K, McCormick F, Aburatani H, Yano T, Osuga Y, Fujii T. Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423. PLoS One. 2014; 9(2):e87220.
    View on PubMed
  5. Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann CO, Hennigan R, Huson S, Ingram D, Kissil J, Korf BR, Legius E, Packer RJ, McClatchey AI, McCormick F, North K, Pehrsson M, Plotkin SR, Ramesh V, Ratner N, Schirmer S, Sherman L, Schorry E, Stevenson D, Stewart DR, Ullrich N, Bakker AC, Morrison H. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A. 2014 Mar; 164(3):563-78.
    View on PubMed
  6. Salt MB, Bandyopadhyay S, McCormick F. Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation. Cancer Discov. 2014 Feb; 4(2):186-99.
    View on PubMed
  7. Yuan TL, McCormick F. Killing Tumors by Keeping Ras and PI3' Kinase Apart. Cancer Cell. 2013 Nov 11; 24(5):562-3.
    View on PubMed
  8. Nan X, Collisson EA, Lewis S, Huang J, Tamgüney TM, Liphardt JT, McCormick F, Gray JW, Chu S. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A. 2013 Nov 12; 110(46):18519-24.
    View on PubMed
  9. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F, Gray JW. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013 Oct 14; 24(4):450-65.
    View on PubMed
  10. Lyons J, Bastian BC, McCormick F. MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A. 2013 Aug 20; 110(34):13845-50.
    View on PubMed
  11. Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell. 2013 May 13; 23(5):594-602.
    View on PubMed
  12. McCormick F, Cvetanovich GL, Kim JM, Harris JD, Gupta AK, Abrams GD, Romeo AA, Provencher MT. An assessment of the quality of rotator cuff randomized controlled trials: utilizing the Jadad score and CONSORT criteria. J Shoulder Elbow Surg. 2013 Sep; 22(9):1180-5.
    View on PubMed
  13. Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 2013 Jan; 3(1):112-23.
    View on PubMed
  14. Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernández H, Burlingame AL, McCormick F. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev. 2012 Jul 1; 26(13):1421-6.
    View on PubMed
  15. Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One. 2012; 7(5):e37431.
    View on PubMed
  16. McCormick F. Cancer therapy based on oncogene addiction. J Surg Oncol. 2011 May 1; 103(6):464-7.
    View on PubMed
  17. Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, Melese T, Munster PN, Nadaf S, Packer RJ, Sebolt-Leopold J, Viskochil DH. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet. 2011 May 15; 157C(2):136-46.
    View on PubMed
  18. Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer. 2011 Mar; 2(3):359-72.
    View on PubMed
  19. McCormick F. Mutant onco-proteins as drug targets: successes, failures, and future prospects. Curr Opin Genet Dev. 2011 Feb; 21(1):29-33.
    View on PubMed
  20. Lee SH, McCormick F, Saya H. Mad2 inhibits the mitotic kinesin MKlp2. J Cell Biol. 2010 Dec 13; 191(6):1069-77.
    View on PubMed

Go to UCSF Profiles, powered by CTSI